Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy

NCT00687596 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

52

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated due to safety concerns

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: TAC-101
DRUG: Placebo

Sponsor

Taiho Oncology, Inc.

Collaborators

[object Object]